Introduction
============

Oesophagus carcinoma is a common malignancy in China and its incidence in 2009 was 22.1 per 100,000 population.[@b1] Higher incidence has been reported in southern China including Shantou. About 15% of oesophageal cancers arise in the upper thoracic region of the oesophagus. Because of its more posteriorly located anatomy and proximity to major nerves and blood vessels which make surgery less accessible, radiotherapy is one of the main treatment modality for upper thoracic carcinoma of oesophagus.[@b2] However, radiotherapy is not without challenges because these tumours are anatomically close to the spinal cord and the treatment region always experiences great changes in body contour.[@b3] Recently, static beam conventional beam intensity-modulated radiotherapy (IMRT) has been proven to have dosimetric advantages over the conventional three-dimensional radiotherapy by some studies, in which better dose coverage to the target and sparing of organs at risk (OARs) have been reported.[@b4]--[@b6] However, conventional IMRT requires a relatively longer treatment time (TT), which may increase the risk of patient movement during treatment,[@b7] resulting in a less accurate treatment. Since the target dose demonstrate great dose gradients at the boundary, a slight shift by the patient can result in dramatic dosimetric changes leading to detrimental results to the patient.

To overcome the problem, a recently developed technology utilising flattening filter-free (FFF) radiation beams has been introduced to the linear accelerator. The main purpose of FFF is to accelerate the speed of dose delivery because the attenuation of radiation by the flattening filter at the gantry head has been removed.[@b8],[@b9] Because of this, a dose rate of as high as 2400 MU/min can be delivered, which is about four times faster than the commonly used dose rate. Another accompanied advantage of FFF is that the dose just outside the treatment field can be reduced due to the reduction of side scatter radiation and multileaf collimator (MLC) leakage.[@b10] For the FFF beams, with the use of the modulation effect of dynamic MLC in IMRT, the problem of a nonuniform, conical fluence distribution can be largely solved. Recent trials of FFF have demonstrated its applications in IMRT and stereotactic body radiotherapy (SBRT) for various malignant diseases.[@b11]--[@b13] Apart from the potential reduction of treatment delivery time, our study aimed to evaluate the dosimetric impact of using FFF beams in IMRT for early-stage upper thoracic oesophageal cancer. If the dosimetric outcome of the FFF plans were comparable or superior to the conventional IMRT plans, they would have the potential to become a more favourable treatment due to its expected shortened TT.

Methods
=======

Eleven patients (eight males and three females) with primary stage I and II upper thoracic oesophageal cancer treated by radiotherapy between March and September 2010 were retrospectively recruited. The study was approved by the institutional review board of the cancer hospital and all patient information was anonymised throughout the study. The length of the lesions ranged between 4.5 and 10.5 cm, with the gross tumour volume (GTV) ranging from 19.5 to 51.0 cm^3^ (mean 35.1±8.5 cm^3^).

During CT, patients lied in supine position with both arms placed at the side of the body. A thermoplastic shell was used to immobilise the head and neck region. The CT was conducted using Brillance Big Bore (Philips, Eindhoven, the Netherlands) with patients under normal breathing condition. The scan covered the whole volume of the lung with a slice thickness of 3 mm. The DICOM CT data of each patient were transferred to the Eclipse treatment planning system (TPS) (Version 10.0; Varian Medical Systems, Palo Alto, CA). The target volumes and OARs were delineated in the respective CT slices. The GTV contained the oesophageal tumour and the adjacent major nodes. The clinical target volume that was prescribed a dose of 64 Gy (CTV~64~) included the GTV plus the high-risk region, which was to add margins of 15--20 mm and 15 mm in the longitudinal and transverse direction, respectively. The CTV~54~ (clinical target volume was prescribed 54 Gy) was delineated by adding the mediastinal and supraclavicular lymphatics to the CTV~64~. The planning target volume (PTV) was formed by expanding the CTV by 5 mm in all directions. The OARs included the lungs and spinal cord. A margin of 5 mm was added to form the planning organ at risk of the spinal cord (PRV). Because the lesion at upper thoracic of the thoracic oesophagus was at considerable distance from the heart and the dose to this organ was expected to be very low, it was not included as OAR in the study.

For each patient, two IMRT plans were computed using conventional beams (Con-P) and FFF beams (FFF-P), respectively. Both plans employed a 5-beam arrangement with gantry angles at 0°, 72°, 144°, 216°, and 288°, which was a standard practice in the local department. The intensity-modulated beams were generated by dynamic MLC from the TrueBeam linear accelerator (Varian Medical Systems) using 6 MV photons. The dose rates were set at 600 MU/min and 1400 MU/min for the Con-P and FFF-P, respectively. The maximum dose rate 2400 MU/min was not used because the dosimetric reliability was not yet verified. Both plans were prescribed with 64 Gy to PTV1 and 54 Gy to PTV2 in 32 fractions. The optimisation parameters including the dose constraints of the targets and OARs were set for the optimisation of both Con-P and FFF-P plans according to the local protocol as shown in Table[1](#tbl1){ref-type="table"}. All plans were computed by the same planner and the dose calculation was done using the analytical anisotropic algorithm (AAA) with grid size of 0.25 × 0.25 cm^2^.

###### 

Dose constraints for target volume and organs at risk in the computation of conventional IMRT plan (Con-P) and flattening filter-free IMRT plan (FFF-P)

  Structures         Dose constraints
  ------------------ ------------------
  PTV1               95% ≥ 64 Gy
  *V*~105~ ≤ 5%      
  *D*~min~ ≥ 60 Gy   
  *D*~max~ ≤ 70 Gy   
  PTV2               95% ≥ 54 Gy
  Spinal cord        *D*~max~ ≤ 40 Gy
  Spinal cord PRV    *D*~max~ ≤ 45 Gy
  Lung               *V*~20~ ≤ 25%
  *V*~30~ ≤ 20%      

PTV, Planning target volume; PRV, planning organ at risk volume; *D*~min,~ minimum dose; *D*~max~, maximum dose; *V*~105,~ volume of structure receiving 105% dose level; *V*~20~ and *V*~30,~ volume of structure receiving 20 Gy and 30 Gy respectively.

After the production of the treatment plans, the doses to the targets and OARs were recorded from their respective dose volume histograms (DVHs). For the dose analysis of PTV1 and PTV2, their *D*~mean~ (mean dose), *D*~5~ (dose received by 5% of volume), *D*~min~ (minimum dose), *V*~95~ (volume received 95% prescribed dose), and *V*~105~ (volume received 105% prescribed dose) were used. In addition, the conformity index (CI) and homogeneity index (HI) were also used for PTV1. The calculation of CI was using the (*V*~T,ref~/*V*~T~) × (*V*~T,ref~/*V*~ref~) formula,[@b14] while the HI was calculated by *D*~5~/*D*~95,~[@b15] where *V*~T,ref~ was the volume of PTV1 received the prescribed dose 64 Gy, *V*~T~ was the volume of PTV1, *V*~ref~ was the volume of the 64 Gy isodose volume, *D*~5~ and *D*~95~ were the doses received by 5% and 95% of PTV1, respectively. For CI and HI, the closer the value to 1.0, the better would be the target conformity and homogeneity, respectively. *D*~max~ was used for the recording the dose to spinal cord and its PRV, while for the lung, *V*~5~, *V*~10~, *V*~20~, and *V*~30~ (volume of lung received 5, 10, 20, and 30 Gy, respectively) were used. In addition, the treatment parameters including the monitor units (MU) and TT for each treatment plan were also recorded for evaluation. The TT was defined as the radiation delivery time and did not include the setup time. The TT and MU were generated from the TPS. The mean values (and standard deviations) of all the parameters for Con-P and FFF-P in all the patients were calculated and compared. Paired *t*-test or Wilcoxon signed-rank test was used to evaluate the significance of their differences depending on the normality of the data, and *P* value of \<0.05 was defined as significant difference.

Results
=======

All IMRT treatment plans produced met the dose requirements set for optimisation. Based on the DVHs of the target volumes (Fig.[1](#fig01){ref-type="fig"}), the dose patterns were fairly similar between Con-P and FFF-P. Both the PTV1 and PTV2 of FFF-P showed higher *D*~5~ than that of Con-P (*P* = 0.046 and 0.043, respectively) (Table[2](#tbl2){ref-type="table"}) and there was no significant different in the CI and HI between the two plans. For the OARs, all the dose parameters did not show any significant difference between the two sets of plans except for the *V*~5~ and *V*~10~ of the lung, in which the FFF-P presented with a significantly lower dose (Table[3](#tbl3){ref-type="table"} and Fig.[1](#fig01){ref-type="fig"}). For the treatment delivery parameters, an increase of 54% in the mean MU was found in the FFF-P relative to the Con-P (*P* \< 0.001), while the mean TT, which was the average of the TT for the 11 patients, was reduced by 18.4% when compared with the Con-P (*P* = 0.021) (Table[4](#tbl4){ref-type="table"}).

###### 

Comparison of target volume dose parameters between Con-P and FFF-P

  Structure       Parameter        Con-P         FFF-P                                    *P* value
  --------------- ---------------- ------------- ---------------------------------------- -----------
  PTV1            *D*~mean~ (Gy)   66.5 ± 0.4    66.5 ± 0.3                               0.990
  *D*~5~ (Gy)     68.3 ± 0.7       68.7 ± 0.6    0.046[\*](#tf2-2){ref-type="table-fn"}   
  *D*~min~ (Gy)   58.1 ± 1.5       58.4 ± 1.8    0.676                                    
  *V*~95~ (%)     99.9 ± 0.1       99.9 ± 0.1    1.000                                    
  *V*~105~ (%)    32.4 ± 15.5      32.8 ± 12.3   0.165                                    
  CI              0.86 ± 0.03      0.85 ± 0.03   0.444                                    
  HI              1.07 ± 0.01      1.07 ± 0.01   1.000                                    
  PTV2            *D*~mean~ (Gy)   63.0 ± 1.1    63.0 ± 1.1                               1.000
  *D*~5~ (Gy)     68.1 ± 0.6       68.4 ± 0.6    0.043[\*](#tf2-2){ref-type="table-fn"}   
  *D*~min~ (Gy)   45.9 ± 1.0       45.7 ± 1.3    0.690                                    
  *V*~95~ (%)     99.7 ± 0.2       99.6 ± 0.2    0.255                                    
  *V*~105~ (%)    97.9 ± 0.7       94.9 ± 5.6    0.093                                    

HI, homogeneity index; CI, conformity index; PTV, planning target volume; *D*~mean~, mean dose; *D*~5~, dose received by 5% of volume; *D*~min,~ minimum dose; *V*~95,~ volume received 95% prescribed dose; *V*~105~, volume received 105% prescribed dose; SD, standard deviation.

Significant difference.

###### 

Comparison of organs at risk dose parameters between Con-P and FFF-P

  Structure         Parameter        Con-P         FFF-P                                    *P* value
  ----------------- ---------------- ------------- ---------------------------------------- -----------
  Spinal cord       *D*~max~ (Gy)    38.6 ± 0.8    38.4 ± 0.8                               0.564
  Spinal cord-PRV   *D*~max~ (Gy)    45.3 ± 1.6    45.2 ± 1.7                               0.888
  Lung              *D*~mean~ (Gy)   32.4 ± 15.5   32.8 ± 12.3                              0.947
  *V*~5~(%)         47.3 ± 13.6      46.7 ± 13.5   0.045[\*](#tf3-2){ref-type="table-fn"}   
  *V*~10~(%)        39.6 ± 11.5      39.1 ± 11.1   0.043[\*](#tf3-2){ref-type="table-fn"}   
  *V*~20~(%)        24.7 ± 6.8       24.1 ± 6.6    0.836                                    
  *V*~30~(%)        8.6 ± 2.5        8.7 ± 2.5     0.726                                    

*D*~max~, maximum dose; *D*~mean~, mean dose; *V*~5~, *V*~10~, *V*~20~ and *V*~30~, volume of lung received 5, 10, 20 and 30 Gy respectively; PRV, planning organ at risk volume; SD, standard deviation.

Significant difference.

###### 

Comparison of monitor unit (MU) and treatment time (TT) between Con-P and FFF-P

  Parameter   Con-P      FFF-P        *P* value
  ----------- ---------- ------------ ------------------------------------------
  MU          663 ± 71   1020 ± 106   \<0.001[\*](#tf4-2){ref-type="table-fn"}
  TT (sec)    174 ± 20   142 ± 12     0.002[\*](#tf4-2){ref-type="table-fn"}

SD, standard deviation.

Significant difference.

![Comparison of dose volume histograms (DVHs) for the targets and organs at risk between Con-P and FFF-P. Con-P, conventional IMRT plan; FFF-P, flattening filter-free IMRT plan; PRV, planning organ at risk volume; PTV, planning target volume; SC, spinal cord.](jmrs0062-0108-f1){#fig01}

Discussion
==========

Five beam IMRT has been a routine technique used to treat upper thoracic oesophageal cancer in the local department. The introduction of FFF beams in the more advanced linear accelerators greatly accelerates the treatment speed and shortens the beam on time in such treatments. In the radiotherapy of oesophageal cancer patients who are often physically weak, reducing the TT will certainly be a benefit to the patients. Since hypofractionation treatment for oesophageal cancer has been a current trend, which involves higher dose per fraction so as to improve the biological effect of radiation, the application of FFF in such scheme would be useful to keep TT short. Recent studies reported that the advantages of FFF increased the beam output near the central axis and reduced the out-of-field and whole body dose during irradiation.[@b16] This would lower the risk of complication and development of secondary cancer due to low-dose irradiation.

Our study showed that the IMRT plans using both conventional beams (Con-P) and FFF beams (FFF-P) met the dosimetric requirements for the treatment of upper thoracic oesophageal cancer patients. Many of the dose parameters from the plans of the two different treatment delivery methods were similar (Fig.[2](#fig02){ref-type="fig"}). Although the FFF-P produced a relatively higher *D*~5~ (indicator of the maximum dose) in the PTVs, it was not expected to produce any clinical difference compared with the Con-P in these patients because the absolute difference was minimal. There was also not much difference in the OAR doses between the two different plans. This implied that there was no obvious advantage of the FFF-P over the Con-P in the sparing of OARs. However, the significant difference in the low-dose volume of the lung (*V*~5~ and *V*~10~) implied that FFF-P may be able to reduce the stochastic effect to the lung, such as carcinogenesis. Such advantage could be accounted by the less scatter radiation from the FFF beam relative to the conventional beam.

![Comparison of dose distribution of a representative case in transverse, coronal and sagittal planes between Con-P (Left) and FFF-P (Right). Con-P, conventional IMRT plan; FFF-P, flattening filter-free IMRT plan.](jmrs0062-0108-f2){#fig02}

Our results were slightly different from a similar study on advanced oesophageal cancers, which reported that FFF beams had the potential of reducing the dose to OARs and the healthy tissues.[@b17] The main reason for this difference was because our study was focused on early-stage patients with relatively small tumour volume (GTV \< 51.0 cm^3^). Smaller tumours were usually more distant from the OARs and therefore both techniques could perform well in sparing these organs resulting in relatively small dosimetric differences. One should note that the calculation algorithm of the TPS would have an impact on the dosimetric outcome as the treatment region was at the thorax, where there was interface between low-density lung tissue and high-density bone. The AAA algorithm used in this study was proved to be better than the pencil beam convolution algorithm.[@b18] However, it was expected that the calculation accuracy would further be improved if the Acuros XB algorithm[@b19] was used.

With regard to the treatment delivery parameters, FFF-P required higher MU but a shorter TT. This phenomenon could be explained by the fact that the un-flattened beam with a much higher intensity around the central axis, this required more MLC modulations to produce a more uniform dose profile and therefore created higher MU for the radiation beams. However, removal of the flattening filter has greatly increased the dose output by two to threefold and the time required to deliver the total MU was reduced, which had outweighed the time needed by the increased MU. This was in line with the several previous studies in which reduction of TT of 20--50% have been reported.[@b17],[@b20],[@b21] Because of this advantage, the use of FFF beams has been extended to VMAT treatment of nasopharynx[@b22] and prostate[@b23] cancers. Nevertheless, despite the FFF beam technology demonstrated attractive practical advantages over the conventional beam IMRT, the understanding of the biological effect of such a high dose rate treatment on body tissues which may have consequence on late toxicities is still not certain and needs to be proven by longer term clinical studies.

Conclusion
==========

IMRT with conventional beams (Con-P) and FFF beams (FFF-P) were able to achieved satisfactory dosimetric outcome for early stage upper thoracic oesophageal cancer patients. FFF-P was more effective in sparing the lung tissue from low dose and reduced the mean TT by ∼20% compared with Con-P. Long term clinical studies are recommended to evaluate the radiobiological effects of FFF beams.
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